



| | | | |
|---------------------------------|---|---------------------------|---------------------------|
| | | EMLc | ATC codes: L01BA01 |
| Indication | Lymphoid leukaemia, not elsewhere classified | ICD11 code: 2C03.3 | |
| INN | Methotrexate | | |
| Medicine type | Chemical agent | | |
| List type | Complementary (EML) (EMLc) | | |
| Formulations | Parenteral > General injections > IV: 50 mg in vial (as sodium salt) ; 50 mg per 2 mL ; 1000 mg per 10 mL concentrated injection Oral > Solid: 2.5 mg (as sodium salt) | | |
| EML status history | First added in 2015 (TRS 994) Changed in 2023 (TRS 1049) | | |
| Sex | All | | |
| Age | Also recommended for children | | |
| Therapeutic alternatives | The recommendation is for this specific medicine | | |
| Patent information | Patents have expired in most jurisdictions Read more about patents .  | | |
| Tags | Cancer | | |
| Wikipedia | Methotrexate  | | |
| DrugBank | Methotrexate  | | |

Summary of evidence and Expert Committee recommendations

Following the review of the age-appropriateness of formulations on the EMLc, the Expert Committee recommended the inclusion of additional dose forms of methotrexate (Injection: 50 mg/2 mL and Concentrated injection: 1000 mg/10 mL) to the EML and EMLc.

[Expert Committee report](#) 

